Trial Profile
Phase II study of antineoplastons A10 and AS2-1 infusions in patients with ependymoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Ependymoma
- Focus Adverse reactions; Therapeutic Use
- 28 Dec 2016 Status changed from active, no longer recruiting to discontinued.
- 05 Dec 2007 New trial record.